Dennis M. Fenton
CIK: 0001184627
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.
Transaction History
| TRAX | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 3,015 | $72K | 6/18/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2025 | View on chart |
| ANAB | ▼ Sell | Open Market | 1,950 | $45K | 6/21/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 3,900 | $0 | 6/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TRAX Announces $200M Private Placement and Analyst Upgrades
First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.
TRAX Announces $200M Private Placement and Analyst Upgrades. First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.